Literature DB >> 15305143

Psilocybin impairs high-level but not low-level motion perception.

Olivia L Carter1, John D Pettigrew, David C Burr, David Alais, Felix Hasler, Franz X Vollenweider.   

Abstract

The hallucinogenic serotonin(1A&2A) agonist psilocybin is known for its ability to induce illusions of motion in otherwise stationary objects or textured surfaces. This study investigated the effect of psilocybin on local and global motion processing in nine human volunteers. Using a forced choice direction of motion discrimination task we show that psilocybin selectively impairs coherence sensitivity for random dot patterns, likely mediated by high-level global motion detectors, but not contrast sensitivity for drifting gratings, believed to be mediated by low-level detectors. These results are in line with those observed within schizophrenic populations and are discussed in respect to the proposition that psilocybin may provide a model to investigate clinical psychosis and the pharmacological underpinnings of visual perception in normal populations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15305143     DOI: 10.1097/00001756-200408260-00023

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  19 in total

Review 1.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 2.  The behavioral pharmacology of hallucinogens.

Authors:  William E Fantegrossi; Kevin S Murnane; Chad J Reissig
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

3.  Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users.

Authors:  José Carlos Bouso; Josep Maria Fábregas; Rosa Maria Antonijoan; Antoni Rodríguez-Fornells; Jordi Riba
Journal:  Psychopharmacology (Berl)       Date:  2013-06-21       Impact factor: 4.530

Review 4.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

5.  Perceptual measurement in schizophrenia: promising electrophysiology and neuroimaging paradigms from CNTRICS.

Authors:  Pamela D Butler; Yue Chen; Judith M Ford; Mark A Geyer; Steven M Silverstein; Michael F Green
Journal:  Schizophr Bull       Date:  2011-09-02       Impact factor: 9.306

6.  Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.

Authors:  Frederick S Barrett; Theresa M Carbonaro; Ethan Hurwitz; Matthew W Johnson; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2018-07-30       Impact factor: 4.530

7.  Dopamine Activation Preserves Visual Motion Perception Despite Noise Interference of Human V5/MT.

Authors:  Nada Yousif; Richard Z Fu; Bilal Abou-El-Ela Bourquin; Vamsee Bhrugubanda; Simon R Schultz; Barry M Seemungal
Journal:  J Neurosci       Date:  2016-09-07       Impact factor: 6.167

8.  Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.

Authors:  Olivia L Carter; Felix Hasler; John D Pettigrew; Guy M Wallis; Guang B Liu; Franz X Vollenweider
Journal:  Psychopharmacology (Berl)       Date:  2007-09-14       Impact factor: 4.530

9.  Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.

Authors:  Matthew J Baggott; Jennifer D Siegrist; Gantt P Galloway; Lynn C Robertson; Jeremy R Coyle; John E Mendelson
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

Review 10.  Animal models and measures of perceptual processing in schizophrenia.

Authors:  Steven J Siegel; John C Talpos; Mark A Geyer
Journal:  Neurosci Biobehav Rev       Date:  2013-07-15       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.